Allena Pharmaceuticals

OverviewSuggest Edit

Allena Pharmaceuticals is a company that develops and commercializes non-systemic protein therapeutics to treat metabolic and orphan diseases. It is focused on treating complex metabolic conditions that can lead to significant and costly health complications. The company aims to reduce the burden of toxic metabolites such as oxalate and uric acid, which can build up and lead to complications such as hyperoxaluria and kidney stones (nephrolithiasis) in the case of oxalate, or hyperuricemia and gout in the case of uric acid.

TypePublic
Founded2011
HQNewton, US
Websiteallenapharma.com

Latest Updates

Employees (est.) (Mar 2020)34(-30%)
Share Price (Aug 2020)$1.5
Cybersecurity ratingAMore

Key People/Management at Allena Pharmaceuticals

Hugh Wight

Hugh Wight

Vice President of Technical Operations
Louis Brenner

Louis Brenner

President and Chief Executive Office
Edward Wholihan

Edward Wholihan

CFO
Annamaria Kausz

Annamaria Kausz

Chief Medical Officer
Geoffrey Swire

Geoffrey Swire

VP, Program & Alliance Management
Stephen Yu

Stephen Yu

VP, Quality Assurance
Show more

Allena Pharmaceuticals Office Locations

Allena Pharmaceuticals has offices in Newton and Sudbury
Newton, US (HQ)
1 Executive Park Dr # 202
Sudbury, US
142B North Road
Show all (2)

Allena Pharmaceuticals Financials and Metrics

Allena Pharmaceuticals Revenue

USD

Net income (Q2, 2020)

(7.0m)

EBIT (Q2, 2020)

(6.6m)

Market capitalization (10-Aug-2020)

56.4m

Closing stock price (10-Aug-2020)

1.5

Cash (30-Jun-2020)

26.5m

EV

38.2m
Allena Pharmaceuticals's current market capitalization is $56.4 m.
Annual
USDFY, 2017FY, 2018FY, 2019

General and administrative expense

5.4m9.2m9.7m

R&D expense

15.5m26.4m37.2m

Operating expense total

21.0m35.6m46.9m

Interest expense

700.0k55.0k
Quarterly
USDQ3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

General and administrative expense

1.4m2.0m2.3m2.4m2.4m2.7m2.5m2.9m2.8m

R&D expense

2.9m5.9m5.9m7.3m9.1m8.6m10.8m4.6m3.8m

Operating expense total

4.4m8.0m8.1m9.7m11.6m11.3m13.3m7.5m6.6m

EBIT

(4.4m)(8.0m)(8.1m)(9.7m)(11.6m)(11.3m)(13.3m)(7.5m)(6.6m)
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

94.5m61.6m30.0m

Prepaid Expenses

1.5m2.8m3.0m

Current Assets

96.0m64.5m33.0m

PP&E

127.0k514.0k401.0k
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(21.6m)(35.6m)(47.3m)

Depreciation and Amortization

73.0k78.0k163.0k

Accounts Payable

199.0k441.0k972.0k

Cash From Operating Activities

(21.1m)(31.8m)(43.6m)
Quarterly
USDQ3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(15.0m)(7.9m)(16.5m)(26.0m)(11.4m)(22.7m)(36.0m)(7.6m)(14.6m)

Depreciation and Amortization

53.0k19.0k27.0k44.0k40.0k79.0k121.0k41.0k83.0k

Accounts Payable

150.0k529.0k(726.0k)(1.0k)534.0k216.0k1.5m(1.3m)(2.5m)

Cash From Operating Activities

(14.2m)(6.9m)(14.9m)(23.1m)(9.8m)(22.6m)(31.7m)(8.6m)(15.3m)
USDQ3, 2017

Financial Leverage

-0.5 x
Show all financial metrics

Allena Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Allena Pharmaceuticals Online and Social Media Presence

Embed Graph

Allena Pharmaceuticals News and Updates

Allena Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update

-- Expanding URIROX-2 Trial Sites; Interim Analysis on Track for the First Quarter of 2022 –-

Allena Pharmaceuticals Increases Previously Announced Bought Deal to $6.7 Million

NEWTON, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announce…

Thinking about buying stock in Tenax Therapeutics, Allena Pharmaceuticals, Trevena, Adaptimmune Therapeutics, or Aurora Cannabis?

NEW YORK, June 2, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TENX, ALNA, TRVN, ADAP, and ACB. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Allena Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update

-- Revised URIROX-2 Trial Design to Potentially Reduce Size and Cost of Trial -- -- Finalized Protocol and Selected Contract Research Organization for Phase 1 Clinical Trial of ALLN-346 --

Allena Pharmaceuticals Reports Fourth Quarter 2019 and Full Year 2019 Financial Results and Provides Business Update

-- Streamlined URIROX-2 Design Potentially Reduces Target Length and Cost of Trial -- -- Regulatory Engagement on Registrational Path for Reloxaliase in High-Risk Enteric Hyperoxaluria (EH) Patients with Chronic Kidney Disease (CKD) Expected in 2Q 2020 --

Allena Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

 -- Reported Positive Topline Results from Pivotal Phase 3 URIROX-1 Trial of Reloxaliase in Enteric Hyperoxaluria (EH), with Statistically Significant Reduction in Urinary Oxalate (UOx) Compared to Placebo -- -- Reported Positive Data from Study 206 of Reloxaliase, Demonstrating Substantial Plasma O…
Show more

Allena Pharmaceuticals Blogs

Allena Pharmaceuticals Provides Updates on Reloxaliase Development Program and Corporate Activities

– Prioritizing Development of Reloxaliase for Patients with Enteric Hyperoxaluria (EH) – – Plan to Re-Engage with U.S. Food and Drug Administration ( FDA ) to Evaluate Opportunities to Streamline URIROX-2, Second Pivotal Phase 3 Trial of Reloxaliase in EH – – Implementing Measures to Reduce

Allena Pharmaceuticals to Present at Evercore ISI 2nd Annual HEALTHCONx Conference

Allena Pharmaceuticals to Present at Evercore ISI 2nd Annual HEALTHCONx Conference Content Import Mon, 11/25/2019 - 08:01 Allena Pharmaceuticals to Present at Evercore ISI 2nd Annual HEALTHCONx Conference November 25, 2019 This release is a backfill from a Ne…

Allena Pharmaceuticals to Present New Data on Reloxaliase and ALLN-346 Development Programs at Upcoming ASN Kidney Week and ACR/ARP Annual Meeting

Allena Pharmaceuticals to Present New Data on Reloxaliase and ALLN-346 Development Programs at Upcoming ASN Kidney Week and ACR/ARP Annual Meeting Kerry.Russell@… Thu, 10/17/2019 - 08:02 Allena Pharmaceuticals to Present New Data on Reloxaliase and ALLN-346 Development Programs at Upcoming…

Allena Pharmaceuticals to Participate in Upcoming Investor Conferences in September

Allena Pharmaceuticals to Participate in Upcoming Investor Conferences in September Content Import Thu, 08/29/2019 - 08:01 Allena Pharmaceuticals to Participate in Upcoming Investor Conferences in September August 29, 2019 This release is a backfill from a Ne…

Allena Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update

-- Interim Data from Study 206 Demonstrated Substantial Treatment Effect in Patients with Enteric Hyperoxaluria and Advanced Chronic Kidney Disease, Including Robust Reductions in Both Urine and Plasma Oxalate -- -- Closed $10.0 Million Registered Direct Offering, Extending Cash Runway into the

Allena Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference

Allena Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference Content Import Tue, 08/06/2019 - 08:01 Allena Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference August 6, 2019 This release is a backfill from a News Wire …
Show more

Allena Pharmaceuticals Frequently Asked Questions

  • When was Allena Pharmaceuticals founded?

    Allena Pharmaceuticals was founded in 2011.

  • Who are Allena Pharmaceuticals key executives?

    Allena Pharmaceuticals's key executives are Hugh Wight, Louis Brenner and Edward Wholihan.

  • How many employees does Allena Pharmaceuticals have?

    Allena Pharmaceuticals has 34 employees.

  • Who are Allena Pharmaceuticals competitors?

    Competitors of Allena Pharmaceuticals include Biogen, MyoKardia and Athersys.

  • Where is Allena Pharmaceuticals headquarters?

    Allena Pharmaceuticals headquarters is located at 1 Executive Park Dr # 202, Newton.

  • Where are Allena Pharmaceuticals offices?

    Allena Pharmaceuticals has offices in Newton and Sudbury.

  • How many offices does Allena Pharmaceuticals have?

    Allena Pharmaceuticals has 2 offices.